"Much-Needed Win": Novo Shares Jump Most In Nearly Two Years After US Approval Of Wegovy Obesity Pill Novo Nordisk shares in Europe jumped the most in nearly two years after the U.S. FDA approved the Wegovy pill, a once-daily 25 mg oral semaglutide, for long-term weight loss, weight maintenance, and......